Access ESTRING® (estradiol vaginal ring) 2 mg
materials to help your patients

Click below to receive the following items for your office:

ESTRING Savings Cards and Samples
Eligible patients pay no more than $15* for their next 4 ESTRING prescriptions.
— Note: Includes ESTRING Demonstration Ring.
*Terms and Conditions apply

Click below to order or re-order the following items for your office:

ESTRING Patient Brochure
Use this patient brochure to help educate your patients about postmenopausal vaginal atrophy, and ESTRING.

ESTRING Patient Instructions Tearpad
A tear pad to provide your patients instructions on how to insert and remove ESTRING.

ESTRING Demonstration Ring
Use this demonstration ring (containing no active ingredient) to show your patients the size, flexibility, and proper removal and insertion of ESTRING.

ESTRING Clinical Trifold Brochure
Learn more about the efficacy, safety, and overall patient acceptance of ESTRING with this brochure.

IMPORTANT SAFETY INFORMATION

BOXED WARNING

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) alone. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE combined with medroxyprogesterone acetate (MPA). In the absence of comparable data, these risks should be assumed to be similar for other dosage forms of estrogens.

The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen-alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRING should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (eg, stroke, myocardial infarction), or a history of these known conditions; anaphylactic reaction or known hypersensitivity to ESTRING; liver dysfunction or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid-binding globulin (TBG) levels.

The most frequently reported adverse events associated with ESTRING were headache, leukorrhea, back pain, genital moniliasis, upper respiratory tract infection, vaginitis, and vaginal discomfort/pain.

Please see full Prescribing and Patient Information, including BOXED WARNING.

INDICATION

ESTRING is indicated for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause.

*Terms and Conditions
By using the ESTRING $15 Co-pay Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as "La Reforma De Salud"])
  • The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs
  • Patients must be 18 years or older
  • By using the Card, patients will pay only $15 per prescription. Savings are limited to $100 for each of 4 uses
  • You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  • The Card cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription
  • The Card will be accepted only at participating pharmacies
  • The Card is not health insurance
  • This offer is good only in the United States and Puerto Rico
  • The Card is limited to one per person during this offering period and is not transferable
  • Pfizer reserves the right to rescind, revoke, or amend the Card without notice

Offer expires 12/31/2016.
No membership fees apply.
For help with the ESTRING $15 Co-pay Card,
call 1-800-631-1181, or write:
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
www.pfizer.com

Please scroll for Important Safety Information and Indication

IMPORTANT SAFETY INFORMATION

BOXED WARNING

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) alone. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE combined with medroxyprogesterone acetate (MPA). In the absence of comparable data, these risks should be assumed to be similar for other dosage forms of estrogens.

The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen-alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRING should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (eg, stroke, myocardial infarction), or a history of these known conditions; anaphylactic reaction or known hypersensitivity to ESTRING; liver dysfunction or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid-binding globulin (TBG) levels.

The most frequently reported adverse events associated with ESTRING were headache, leukorrhea, back pain, genital moniliasis, upper respiratory tract infection, vaginitis, and vaginal discomfort/pain.

INDICATION

ESTRING is indicated for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause.